A comprehensive, large-scale meta-analysis published in the esteemed medical journal The Lancet has meticulously scrutinized the purported therapeutic benefits of medicinal cannabis, concluding that current evidence provides no substantial support for its effectiveness in treating prevalent mental health conditions such as anxiety, depression, and post-traumatic stress disorder (PTSD). This extensive investigation represents the most significant undertaking to date that has systematically evaluated both the safety profile and therapeutic efficacy of cannabinoids across a broad spectrum of psychological ailments.
The release of these findings arrives at a critical juncture, coinciding with a significant surge in the reported use of cannabis for medicinal purposes globally. In North America, for instance, approximately 27% of adults aged 16 to 65 have indicated engaging in medical cannabis consumption, with a substantial proportion, roughly half of this group, attributing their use to the management of symptoms related to mental well-being. This widespread adoption, often driven by anecdotal reports and a desire for alternative treatment modalities, underscores the pressing need for robust scientific validation.
Dr. Jack Wilson, the principal investigator of this landmark study and a researcher affiliated with the University of Sydney’s Matilda Centre, articulated that the study’s outcomes necessitate a re-evaluation of the widespread approval and prescription of medicinal cannabis for conditions like anxiety, depression, and PTSD. He posited that the routine, often unmonitored, use of medicinal cannabis might inadvertently contribute more detriment than benefit. This potential harm, he elaborated, could manifest as an exacerbation of existing mental health challenges, an increased susceptibility to psychotic episodes, the development of problematic cannabis use disorder, and crucially, a delay in seeking or receiving treatments that have demonstrated established efficacy.
While the primary focus of the analysis was on its ineffectiveness for the aforementioned mental health conditions, the researchers did identify nascent indications suggesting potential utility for a more select group of disorders. These include the management of cannabis use disorder itself, certain symptoms associated with autism spectrum disorder, insomnia, and involuntary muscle spasms or tics, such as those seen in Tourette’s syndrome. However, Dr. Wilson strongly cautioned against overstating these preliminary observations, emphasizing that the supporting empirical data for these specific applications remains notably weak.
"The overall caliber of evidence underpinning these other conditions, including autism and insomnia, is of low quality," Dr. Wilson stated, highlighting the need for judicious clinical application. He further elaborated that, in the absence of comprehensive medical supervision and appropriate psychotherapeutic interventions, the rationale for employing medicinal cannabis in these contexts is frequently tenuous. He drew a distinction between these emerging areas and well-established therapeutic uses, noting that the efficacy of medicinal cannabis has been more definitively demonstrated in conditions such as reducing seizure frequency in specific forms of epilepsy, alleviating spasticity in individuals diagnosed with multiple sclerosis, and providing relief for certain types of chronic pain. The current study, he reiterated, unequivocally demonstrates that the evidence base for its application in mental health disorders falls significantly short of these established therapeutic roles.
Addressing the specific findings related to autism, Dr. Wilson acknowledged that the study observed some evidence suggesting a potential reduction in symptoms. However, he immediately qualified this by stressing the inherent heterogeneity of the autistic experience. "It is crucial to recognize that there is no single, universal presentation of autism," he explained. "Consequently, any findings suggesting therapeutic benefit for such a diverse condition must be approached with considerable caution and further rigorous investigation."
The research also delved into the intricate relationship between medicinal cannabis and various substance use disorders, revealing a complex and condition-dependent pattern of effects. While cannabis-based interventions showed some promise in aiding individuals struggling with dependence on cannabis itself, a disquieting trend emerged concerning individuals with cocaine-use disorder, where the consumption of cannabis appeared to intensify cravings for cocaine.
Dr. Wilson drew a parallel between the potential role of cannabis in treating cannabis use disorder and established pharmacotherapies like methadone, which are utilized in managing opioid dependence. "Similar to how methadone is employed to address opioid-use disorder," he explained, "cannabis-derived medicines could potentially form an integral component of a comprehensive treatment strategy for individuals experiencing cannabis-use disorder. Specifically, when administered in conjunction with psychological therapies, an oral formulation of cannabis has demonstrated an ability to reduce the frequency of cannabis smoking."
Conversely, the study’s findings regarding cocaine-use disorder presented a starkly different picture. "However, when medicinal cannabis was administered to individuals with cocaine-use disorder, the observed effect was an increase in their cravings for cocaine," Dr. Wilson reported. "This suggests that it should not be considered as a therapeutic option for this specific condition and may, in fact, potentiate or exacerbate cocaine dependence."
The rapid proliferation of medicinal cannabis use, coupled with an increasing rate of prescriptions, has understandably ignited concerns among leading medical organizations worldwide, including prominent bodies such as the American Medical Association. Experts in the field have consistently highlighted a lack of stringent regulatory oversight and a persistent ambiguity surrounding the precise efficacy and safety profiles of these products. This regulatory vacuum can lead to the widespread availability of products with unverified claims and inconsistent quality.
"Our study endeavors to provide a comprehensive and independent assessment of both the potential benefits and the inherent risks associated with cannabis-based medicines," Dr. Wilson emphasized. He articulated that such an evidence-based evaluation is vital to support clinicians in making informed, patient-centered decisions. The ultimate goal, he stated, is to ensure that patients receive treatments that are demonstrably effective while simultaneously minimizing potential harm stemming from the use of ineffective or potentially unsafe cannabis products.
The foundation of these significant findings rests upon a meticulously executed systematic review and meta-analysis, which aggregated data from 54 randomized controlled trials (RCTs). These trials, conducted across diverse geographical locations, spanned a considerable temporal range, from 1980 to 2025, encompassing a wealth of longitudinal data. The research was generously supported by funding from the National Health and Medical Research Council (NHMRC). Several authors, including Wayne Hall and Myfanwy Graham, have disclosed receiving consultation fees from the World Health Organization, and Wayne Hall has provided expert testimony concerning the risks associated with cannabis use. Myfanwy Graham also holds a position as an appropriate member of the Medicinal Cannabis Expert Working Group within the Australian Department of Health, Ageing and Disability, and has received funding from the Therapeutic Goods Administration for independent evidence reviews pertaining to medicinal cannabis. All other contributing authors have declared no competing interests that could have influenced the integrity of the study’s findings.
About the Author
